These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30329020)

  • 21. Active vitamin D is cardioprotective in experimental uraemia but not in children with CKD Stages 3-5.
    Schön A; Leifheit-Nestler M; Deppe J; Fischer DC; Bayazit AK; Obrycki L; Canpolat N; Bulut IK; Azukaitis K; Yilmaz A; Mir S; Yalcinkaya F; Soylemezoglu O; Melk A; Stangl GI; Behnisch R; Shroff R; Bacchetta J; Querfeld U; Schaefer F; Haffner D;
    Nephrol Dial Transplant; 2021 Feb; 36(3):442-451. PubMed ID: 33241290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
    Grabner A; Amaral AP; Schramm K; Singh S; Sloan A; Yanucil C; Li J; Shehadeh LA; Hare JM; David V; Martin A; Fornoni A; Di Marco GS; Kentrup D; Reuter S; Mayer AB; Pavenstädt H; Stypmann J; Kuhn C; Hille S; Frey N; Leifheit-Nestler M; Richter B; Haffner D; Abraham R; Bange J; Sperl B; Ullrich A; Brand M; Wolf M; Faul C
    Cell Metab; 2015 Dec; 22(6):1020-32. PubMed ID: 26437603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.
    Mizobuchi M; Morrissey J; Finch JL; Martin DR; Liapis H; Akizawa T; Slatopolsky E
    J Am Soc Nephrol; 2007 Jun; 18(6):1796-806. PubMed ID: 17513326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
    D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis.
    Panizo S; Carrillo-López N; Naves-Díaz M; Solache-Berrocal G; Martínez-Arias L; Rodrigues-Díez RR; Fernández-Vázquez A; Martínez-Salgado C; Ruiz-Ortega M; Dusso A; Cannata-Andía JB; Rodríguez I
    Nephrol Dial Transplant; 2017 Nov; 32(11):1831-1840. PubMed ID: 28460073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.
    Freundlich M; Quiroz Y; Zhang Z; Zhang Y; Bravo Y; Weisinger JR; Li YC; Rodriguez-Iturbe B
    Kidney Int; 2008 Dec; 74(11):1394-402. PubMed ID: 18813285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excessive fibroblast growth factor 23 promotes renal fibrosis in mice with type 2 cardiorenal syndrome.
    Hao H; Ma S; Zheng C; Wang Q; Lin H; Chen Z; Xie J; Chen L; Chen K; Wang Y; Huang X; Cao S; Liao W; Bin J; Liao Y
    Aging (Albany NY); 2021 Jan; 13(2):2982-3009. PubMed ID: 33460402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac actions of fibroblast growth factor 23.
    Faul C
    Bone; 2017 Jul; 100():69-79. PubMed ID: 27725315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
    Wu-Wong JR; Chen YW; Wessale JL
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocorticoids Decrease Longitudinal Bone Growth in Pediatric Kidney Transplant Recipients by Stimulating the FGF23/FGFR3 Signaling Pathway.
    Delucchi Á; Toro L; Alzamora R; Barrientos V; González M; Andaur R; León P; Villanueva F; Galindo M; Las Heras F; Montecino M; Moena D; Lazcano A; Pinto V; Salas P; Reyes ML; Mericq V; Michea L
    J Bone Miner Res; 2019 Oct; 34(10):1851-1861. PubMed ID: 31099911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4.
    Chuppa S; Liang M; Liu P; Liu Y; Casati MC; Cowley AW; Patullo L; Kriegel AJ
    Kidney Int; 2018 Feb; 93(2):375-389. PubMed ID: 28760335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia.
    Mace ML; Gravesen E; Nordholm A; Hofman-Bang J; Secher T; Olgaard K; Lewin E
    Kidney Int; 2017 Jul; 92(1):165-178. PubMed ID: 28341272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocardial Hypertrophy and Fibrosis Are Associated with Cardiomyocyte Beta-Catenin and TRPC6/Calcineurin/NFAT Signaling in Spontaneously Hypertensive Rats with 5/6 Nephrectomy.
    Bogdanova E; Beresneva O; Galkina O; Zubina I; Ivanova G; Parastaeva M; Semenova N; Dobronravov V
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of fibroblast growth factor 23 production in bone in uremic rats.
    Saji F; Shiizaki K; Shimada S; Okada T; Kunimoto K; Sakaguchi T; Hatamura I; Shigematsu T
    Nephron Physiol; 2009; 111(4):p59-66. PubMed ID: 19339809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease.
    Rayego-Mateos S; Morgado-Pascual JL; Valdivielso JM; Sanz AB; Bosch-Panadero E; Rodrigues-Díez RR; Egido J; Ortiz A; González-Parra E; Ruiz-Ortega M
    J Am Soc Nephrol; 2020 Sep; 31(9):2026-2042. PubMed ID: 32631974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct and indirect effects of fibroblast growth factor 23 on the heart.
    Nakano T; Kishimoto H; Tokumoto M
    Front Endocrinol (Lausanne); 2023; 14():1059179. PubMed ID: 36909314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH.
    Liu ES; Thoonen R; Petit E; Yu B; Buys ES; Scherrer-Crosbie M; Demay MB
    Endocrinology; 2018 May; 159(5):2165-2172. PubMed ID: 29635291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
    Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Loewe C; Marculescu R; Erben R; Oberbauer R
    Trials; 2019 Oct; 20(1):601. PubMed ID: 31651370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast Growth Factor-23-A Potential Uremic Toxin.
    Kuczera P; Adamczak M; Wiecek A
    Toxins (Basel); 2016 Dec; 8(12):. PubMed ID: 27941640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23.
    Matsui I; Oka T; Kusunoki Y; Mori D; Hashimoto N; Matsumoto A; Shimada K; Yamaguchi S; Kubota K; Yonemoto S; Higo T; Sakaguchi Y; Takabatake Y; Hamano T; Isaka Y
    Kidney Int; 2018 Jul; 94(1):60-71. PubMed ID: 29751971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.